Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Mol Cancer Res. 2012 Jul 13;10(11):1440–1450. doi: 10.1158/1541-7786.MCR-12-0158

Figure 3. Modulation of MAPK signaling with GRM1 siRNA.

Figure 3

(A.) Western immunoblots of protein lysates prepared from C8161 pVgRXR or C8161 pVgRXR siGRM1-A13 cells, not treated (NT) or treated with vehicle (DMSO) or with PonA and probed for phosphorylated (pERK1/2) and total ERK1/2 (T-ERK1/2). (B) Quantification of the intensities on the immunoblots from A. with Optiquant software with NT or Veh set as 100%. (C.) Suppression of ERK1/2 phosphorylation in UACC903 TetR siGRM1 clones but not in control UACC903 TetR after doxycycline (10 ng/ml) treatment. Equal loading was assessed with levels of total ERK1/2. (D.) Quantification of the intensities on the immunoblots from C. with Optiquant software. (E.) Suppression of ERK1/2 phosphorylation in 1205 Lu TetR siGRM1 clones and not in 1205 Lu TetR controls after doxycycline (10 ng/ml treatment). Equal loading was shown by levels of total ERK1/2. NT- No treatment, Dox - doxycycline. (F.) Quantification of the intensities on the immunoblots from E. with Optiquant software.